Pharmaceuticals 2010, 3(2), 406-418; https://doi.org/10.3390/ph3020406
Deregulation of Interferon Signaling in Malignant Cells
Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Medical School and Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
Received: 10 December 2009 / Revised: 28 January 2010 / Accepted: 1 February 2010 / Published: 4 February 2010
(This article belongs to the Special Issue Interferons)
Abstract
Interferons (IFNs) are a family of cytokines with potent antiproliferative, antiviral, and immunomodulatory properties. Much has been learned about IFNs and IFN-activated signaling cascades over the last 50 years. Due to their potent antitumor effects in vitro and in vivo, recombinant IFNs have been used extensively over the years, alone or in combination with other drugs, for the treatment of various malignancies. This review summarizes the current knowledge on IFN signaling components and pathways that are deregulated in human malignancies. The relevance of deregulation of IFN signaling pathways in defective innate immune surveillance and tumorigenesis are discussed. View Full-TextKeywords:
interferon; signaling pathways; cancer
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Katsoulidis, E.; Kaur, S.; Platanias, L.C. Deregulation of Interferon Signaling in Malignant Cells. Pharmaceuticals 2010, 3, 406-418.
Related Articles
Article Metrics
Comments
[Return to top]
Pharmaceuticals
EISSN 1424-8247
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert